Stifel raised the firm’s price target on Apellis to $84 from $70 and keeps a Buy rating on the shares. Apellis announced preliminary Q4 results coinciding with the JPM Conference this week and posted a “particularly impressive performance” for Syfovre, the analyst tells investors. Separately, Empaveli continues its steady performance, adds the analyst, who adjusted the firm’s model to “capture the momentum.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APLS:
- Apellis price target raised to $77 from $73 at BofA
- Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
- Apellis reports preliminary FY23 SYFOVRE, EMPAVELI revenue of $366M
- Apellis reports preliminary Q4 SYFOVRE revenue of $138M
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)